R&D	Innovative R&D Home Multiple Sclerosis Franchise Other Neurological/Neurodegenerative Diseases Auto-Immune/Inflammatory Diseases Oncology

Auto-Immune/Inflammatory Diseases

Edratide for Lupus

Teva is developing a CDR1- based peptide derived from a human anti-DNA antibody as a novel approach towards the specific modulation of the auto-immune processes in Lupus. Studies in relevant animal models have shown that this peptide is effective in preventing and treating Lupus-like symptoms.

Phase I studies were completed in 2004. A phase II trial in Systemic Lupus Erythematosus patients is currently on-going.

The development of edratide is based on original research performed by scientists at the Weizmann Institute of Science, Rehovot, Israel. Teva has acquired the exclusive worldwide license for edratide and related peptides.

Selected publications:

Waisman, A. et al.: Proc. Nat. Acad. Sci. (1997);94: 4620-4625
Dayan, M., Segal, R., Sthoeger, Z., Waisman, A., Brosh, N., Elkayam, O., Eilat, E., Fridkin, M. and Mozes, E. J. Clin. Immunol.(2000); 20, 187
Dror L. et al.: J. of clinical immunology (2004);24 :579-590
Sharabi, A., Zinger, H., Zborowsky, M., Sthoeger, ZM., and Mozes, E. Proc. Nat. Acad. Sci. (2006);103 (23): 8810-8815
Sharabi, A., Haviv, A., Zinger, H., Dayan, M., and Mozes, E. J. Clin. Immunol. (2006); 119(2):146-155

TV-3813 for Psoriasis

Teva is developing an olyel alcohol derivative for the topical treatment of psoriasis. TV-3813 was found to be effective in the treatment of experimental delayed- type hypersensitivity in mice and in the treatment of an experimental model of transplanted human psoriatic skin in severe combined immunodificient mice. In these and other experiments, TV-3813 has been shown to be an immune-modulator: It prevents proliferation of human PBMC's exposed to the compound and reduces TNF alpha secretion by these cells and in psoriatic skin.

TV-3813 is currently in the pre-clinical development stage. This development is based on original research initiated by Prof´s. I. Cohen and A. Shinitzky at the Weizmann Institute of Science, Rehovot, Israel and Teva has acquired the exclusive worldwide license for the molecule and related compounds